Masanori Yasuda

List of Publications by Year
in descending order

56	716	471509 17	610901 24
papers	citations	h-index	g-index

57	57	57	1014
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Utility of magnetic resonance imaging for differentiating malignant mesenchymal tumors of the uterus from T2-weighted hyperintense leiomyomas. Japanese Journal of Radiology, 2022, 40, 385-395.	2.4	6
2	Distribution of CD1aâ€positive cells is not different between pseudolymphomatous folliculitis and primary cutaneous marginal zone lymphoma. Journal of Dermatology, 2021, 48, 464-469.	1.2	0
3	The hybrid procedure of thoracoscopic and handâ€assisted laparoscopic resection of an esophageal gastrointestinal stromal tumor: A case report. Asian Journal of Endoscopic Surgery, 2021, 14, 286-289.	0.9	0
4	Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms. In Vivo, 2021, 35, 2425-2432.	1.3	6
5	Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma. Anticancer Research, 2021, 41, 1647-1654.	1.1	9
6	Lethal macrophage-related complications of juvenile myelomonocytic leukemia with a blastic crisis: an autopsy case report. International Journal of Hematology, 2021, 114, 517-523.	1.6	0
7	Tumor immunity is related to ¹⁸Fâ€FDG uptake in thymic epithelial tumor. Cancer Medicine, 2021, 10, 6317-6326.	2.8	5
8	Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cellâ€like features. Thoracic Cancer, 2020, 11, 3609-3613.	1.9	4
9	Uterine intravenous leiomyomatosis with an isolated large metastasis to the right atrium: a case report. Diagnostic Pathology, 2020, 15, 4.	2.0	15
10	Hypoxia-inducible Factor-1Î± Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration. Anticancer Research, 2020, 40, 6791-6798.	1.1	6
11	Successful Bridge-to-Recovery Treatment in a Young Patient with Fulminant Eosinophilic Myocarditis: Roles of a Percutaneous Ventricular Assist Device and Endomyocardial Biopsy. Case Reports in Emergency Medicine, 2019, 2019, 1-8.	0.3	4
12	A unique uterine cervical â€œteratocarcinosarcomaâ€• a case report. Diagnostic Pathology, 2019, 14, 122.	2.0	5
13	Tumor-to-tumor metastasis from appendiceal adenocarcinoma to an ovarian mature teratoma, mimicking malignant transformation of a teratoma: a case report. Diagnostic Pathology, 2019, 14, 88.	2.0	7
14	Association of the hypoxia-inducible factor-1Î± (HIF-1Î±) gene polymorphisms with prognosis in ovarian clear cell carcinoma. Journal of Ovarian Research, 2019, 12, 7.	3.0	1
15	Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a MÃ¼llerian duct lineage: a case report. Diagnostic Pathology, 2019, 14, 54.	2.0	40
16	Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma. Modern Pathology, 2019, 32, 1023-1031.	5.5	35
17	Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. Scientific Reports, 2019, 9, 2397.	3.3	21
18	Association of histone deacetylase expression with histology and prognosis of ovarian cancer. Oncology Letters, 2018, 15, 3524-3531.	1.8	29

#	Article	IF	Citations
19	Preponderance of endometrial carcinoma in elderly patients. Molecular and Clinical Oncology, 2018, 9, 269-273.	1.0	2
20	Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. Journal of Gynecologic Oncology, 2017, 28, e25.	2.2	11
21	A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression. BMC Cancer, 2016, 16, 805.	2.6	9
22	Synchronous mucinous metaplasia and neoplasia of the female genital tract with external urethral meatus neoplasm: A case report. Gynecologic Oncology Reports, 2015, 12, 27-30.	0.6	8
23	A case of ovarian serous adenocarcinoma with tubal intraepithelial carcinoma. The Journal of the Japanese Society of Clinical Cytology, 2015, 54, 318-322.	0.0	0
24	Serous borderline tumor of the ovary with positive endometrial cytology characterized by calcifying deposition. The Journal of the Japanese Society of Clinical Cytology, 2015, 54, 216-220.	0.0	0
25	Immunohistochemical characterization of endometrial carcinomas: Endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis. Journal of Obstetrics and Gynaecology Research, 2014, 40, 2167-2176.	1.3	13
26	Diffusion-weighted MR imaging findings of ovarian adenocarcinofibromas and adenofibromas. Clinical Imaging, 2014, 38, 483-489.	1.5	2
27	Endometrial intraepithelial carcinoma in association with polyp: review of eight cases. Diagnostic Pathology, 2013, 8, 25.	2.0	21
28	Alterations of Hypoxia-Induced Factor Signaling Pathway Due to Mammalian Target of Rapamycin (mTOR) Suppression in Ovarian Clear Cell Adenocarcinoma: In Vivo and in Vitro Explorations for Clinical Trial. International Journal of Gynecological Cancer, 2013, 23, 1210-1218.	2.5	8
29	Long Term Prognostic Implications of Expression of Glucose Transporter-1 and Hexokinase II in Patients with Stage I Uterine Leiomyosarcoma. Acta Histochemica Et Cytochemica, 2012, 45, 147-154.	1.6	7
30	Estrogen-producing endometrioid adenocarcinoma resembling sex cord-stromal tumor of the ovary: a review of four postmenopausal cases. Diagnostic Pathology, 2012, 7, 164.	2.0	18
31	Granulosa cell tumor with activated mTORâ€HIFâ€1Î±â€VEGF pathway. Journal of Obstetrics and Gynaecology Research, 2010, 36, 448-453.	1.3	26
32	Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Annals of Diagnostic Pathology, 2010, 14, 23-29.	1.3	24
33	Therapeutic strategy targeting the mTORâ€“HIFâ€1Î±â€“VEGF pathway in ovarian clear cell adenocarcinoma. Pathology International, 2009, 59, 19-27.	1.3	72
34	Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Archives of Gynecology and Obstetrics, 2009, 279, 789-796.	1.7	26
35	Clear Cell Adenocarcinoma Arising From Adenomyosis. International Journal of Gynecological Pathology, 2009, 28, 262-266.	1.4	18
36	Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1Î±/GLUT-1 expression. Archives of Gynecology and Obstetrics, 2008, 277, 539-546.	1.7	23

#	Article	IF	Citations
37	Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncology Reports, 2008, 19, 111-6.	2.6	29
38	An Up-to-Date Anti-Cancer Treatment Strategy Focusing on HIF-1.ALPHA. Suppression: Its Application for Refractory Ovarian Cancer. Acta Histochemica Et Cytochemica, 2007, 40, 139-142.	1.6	13
39	Usefulness of hypoxia inducible factor-1 alpha in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy. Cancer Detection and Prevention, 2007, 31, 396-401.	2.1	9
40	Localization of Human Papillomavirus-DNA in Cervical Adenocarcinoma Revealed by in Situ Hybridization. The Showa University Journal of Medical Sciences, 2007, 19, 195-200.	0.1	0
41	Ovarian carcinomas with neuroendocrine differentiation: Review of five cases referring to immunohistochemical characterization. Journal of Obstetrics and Gynaecology Research, 2006, 32, 387-395.	1.3	8
42	Availability of CD10 as a Histopathological Diagnostic Marker. Acta Histochemica Et Cytochemica, 2005, 38, 17-24.	1.6	7
43	Utility of Confocal Laser Scanning Microscopy (CLSM): With Reference to Interpretation in Immunostaining. Acta Histochemica Et Cytochemica, 2005, 38, 267-271.	1.6	1
44	Glucose transporter-1 expression in the thyroid gland: Clinicopathological significance for papillary carcinoma. Oncology Reports, 2005, 14, 1499-504.	2.6	27
45	Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer. Oncology Reports, 2005, 13, 1081-7.	2.6	4
46	Serum carbohydrate antigen elevations in endometrial adenocarcinomas: Characterization of DU-PAN-2 expression as a tumor marker. Journal of Obstetrics and Gynaecology Research, 2004, 30, 59-64.	1.3	3
47	Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation. Pathology International, 2004, 54, 451-456.	1.3	13
48	Cytologic three-dimensional imaging for the interpretation of staining profiles: Application of confocal laser scanning microscopy. Diagnostic Cytopathology, 2004, 31, 166-168.	1.0	4
49	Modification of p53 Immunoexpression Associated with Chemotherapy Regimens in Advanced and Refractory Ovarian Cancers. Acta Histochemica Et Cytochemica, 2004, 37, 15-20.	1.6	1
50	Immunohistochemical Expression of Type-1 Carbohydrate Antigens: Availability of DU-PAN-2 on Pathological and Clinical Aspects.. Acta Histochemica Et Cytochemica, 2003, 36, 185-192.	1.6	4
51	Expression of Bone Matrix Proteins in Malignant Myoepithelioma with Extensive Osteoid Formation Occurring in The Maxilla.. Oral Medicine & Pathology, 2003, 8, 31-36.	0.2	1
52	Neuroendocrine Marker Expression in Thyroid Epithelial Tumors. Endocrine Pathology, 2001, 12, 291-300.	9.0	42
53	Differentiation of Necrotic Cell Death With or Without Lysosomal Activation: Application of Acute Liver Injury Models Induced by Carbon Tetrachloride (CCL4) and Dimethylnitrosamine (DMN). Journal of Histochemistry and Cytochemistry, 2000, 48, 1331-1339.	2.5	23
54	Cytologic Study of Ascites and the Endometrium in Ovarian Carcinoma. Acta Cytologica, 1997, 41, 1451-1455.	1.3	23

#	Article	IF	Citations
55	Double squamous cell carcinomas, verrucous type and poorly differentiated type, of the urinary bladder unassociated with bilharzial infection. Pathology International, 1997, 47, 651-654.	1.3	2
56	Iron as a possible aggravating factor for osteopathy in itai-itai disease, a disease associated with chronic cadmium intoxication. Journal of Bone and Mineral Research, 1991, 6, 245-255.	2.8	21